[Featured Stock] SuzenTech Pursues Technology Transfer of Diagnostic Kit to China... "Rapid Diagnosis of 'Wuhan Pneumonia' Possible"

[Asia Economy Reporter Yoo Hyun-seok] SuzenTech is showing strong performance. It appears that news about the company's blood-based tuberculosis diagnostic kit being able to detect pneumonia infection has had an impact.

As of 9:47 AM on the 28th, SuzenTech was trading at 6,950 KRW, up 16.61% (990 KRW) compared to the previous trading day.

According to a media report on the same day, SuzenTech is currently conducting large-scale global field clinical trials in China and recently signed a clinical trial contract with the Shanghai Fudan University Medical School earlier this month. SuzenTech plans to proceed with a general distribution and technology transfer contract for the tuberculosis diagnostic kit in China with Chinese pharmaceutical companies as soon as the clinical results are available. SuzenTech's tuberculosis diagnostic kit diagnoses infection based on tuberculosis bacteria-derived biomarkers and is known to distinguish whether a suspected patient with pneumonia symptoms has pneumonia, tuberculosis, or just a common cold, in addition to determining tuberculosis infection.

As of the 27th, Wuhan pneumonia has resulted in 2,840 confirmed cases across more than 30 provinces in China, with 81 deaths. Additionally, as Wuhan pneumonia spreads globally, confirmed cases have been reported as follows: 8 in Thailand, 5 in the United States, 5 in Australia, 4 each in Korea, Japan, Singapore, and Malaysia, and 3 in France.

This content was produced with the assistance of AI translation services.